Plutux
TransMedics Group, Inc. logo

TransMedics Group, Inc.

TMDX
$84.84
+0.65%
2026-09-03 10:34:14 EDT+$0.55
Healthcare
Medical - Devices
NASDAQ
Active Trading

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide ...

Price Action

$84.84
+0.65%+$0.55
High—
Low—
52W High-45.6%
Rel. vol—
Interval
Range6.5h
Volume—SMA5SMA10
—

Company Overview

TransMedics Group, Inc. (TMDX) is a medical device company focused on revolutionizing organ transplantation. The company's flagship product, the Organ Care System (OCS), is a portable perfusion and monitoring device that maintains donor organs in a near-physiological state, improving their quality and viability for transplantation. The OCS platform includes specialized ...TransMedics Group, Inc. (TMDX) is a medical device company focused on revolutionizing organ transplantation. The company's flagship product, the Organ Care System (OCS), is a portable perfusion and monitoring device that maintains donor organs in a near-physiological state, improving their quality and viability for transplantation. The OCS platform includes specialized modules: OCS LUNG, OCS Heart, and OCS Liver, addressing the most critical transplant needs. TransMedics aims to increase organ utilization, improve patient outcomes, and reduce transplant costs by providing a superior alternative to traditional static cold storage. The company generates revenue through the sale of OCS devices and related consumables, as well as services such as logistics and clinical support. In 2024, TransMedics reported revenues of $667 million, with a gross margin of 58.7% and a net margin of 22.7%, indicating strong profitability. The company is led by founder and CEO Dr. Waleed Hassanein, who established TransMedics in 1998 to address the growing shortage of healthy donor organs. The company operates in the United States and internationally, with strategic collaborations to expand its reach, such as with Mercedes-Benz for logistics and PAD Aviation for a European transplant logistics network. With a workforce of ~898 employees, TransMedics continues to innovate in the field of organ preservation, aiming to improve the lives of patients awaiting transplants and reduce the overall burden of end-stage organ failure.
Founded
1998
Employees
898
CEO
Waleed H. Hassanein
Full Name
TransMedics Group, Inc.
Sector
Healthcare
Industry
Medical - Devices
ROE
32.97%
Market Cap
$2.93B
Current Ratio
6.62
WACC
12.34%
ROIC
5.87%

Contact Information

https://www.transmedics.com
978 552 0900
200 Minuteman Road, Andover, MA 01810

Related stocksMedical - Devices

Browse all US stocks →
About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026